- Home
- PACB vs VSTM Comparison
PACB vs VSTM Comparison
Compare PACB & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACB | VSTM |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.8M | 470.7M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PACB | VSTM |
|---|---|---|
| Price | $1.58 | $6.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $1.67 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 5.5M | 2.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $93,468,000.00 | $30,914,000.00 |
| Revenue This Year | $11.32 | $282.64 |
| Revenue Next Year | $12.13 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.04 | ★ 209.14 |
| 52 Week Low | $0.85 | $4.01 |
| 52 Week High | $2.73 | $11.25 |
Technical Indicators
Market Signals| Indicator | PACB | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 61.51 |
| Support Level | $1.52 | $6.01 |
| Resistance Level | $1.64 | $6.79 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 83.31 | 86.33 |
Price Performance
Historical ComparisonAbout PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.